To build a better VAD: What is needed to make MCS truly competitive with cardiac transplantation for long-term outcomes?
Recommended Citation
Cowger JA, and Potapov E. To build a better VAD: What is needed to make MCS truly competitive with cardiac transplantation for long-term outcomes? JHLT Open 2025;9:100325.
Document Type
Article
Publication Date
8-1-2025
Publication Title
JHLT Open
Abstract
While average survival in patients undergoing durable left ventricular assist device (dLVAD) support now approximate 6 years, the application of therapy remains limited across the globe. Herein we highlight important deficiencies common to present technology and propose device innovations and field corrections that will be necessary to improve acceptance of dLVAD support by both patients and medical providers caring for patients with end-stage heart failure. Pragmatic trials will also be needed to help identify the therapeutic strategy (permanent dLVAD support vs heart transplant vs dLVAD as a bridge to transplant) that affords the best outcomes for a patient's risk profile and total survival goals.
PubMed ID
40808827
Volume
9
First Page
100325
Last Page
100325
